TY - JOUR
T1 - High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma
AU - Baiz, D
AU - Negroni, C
AU - Ferluga, S
AU - Ercolano, E
AU - Adams, C
AU - Hanemann, CO
PY - 2018
Y1 - 2018
N2 - Meningioma is the most common primary tumour affecting the central
nervous system; it is classified as benign (WHO I, ~80%), atypical (WHO II, ~15-20%)
and anaplastic/malignant (WHO III, ~1-3%). The 3-year recurrence rate in WHO I
meningioma is estimated in about 50% and it is much greater in WHO II and III
tumours. MicroRNAs (miRNAs) represent a large class of small RNAs driving
regulation of gene expression at post-transcriptional level and playing a role in cell
proliferation, differentiation, apoptosis and carcinogenesis. Several studies showed
that miRNAs are involved in tumour progression and therefore proposed as diagnostic
tools. Here, we evaluated miRNAs signature in meningioma to identify novel
biomarkers of tumour progression.
AB - Meningioma is the most common primary tumour affecting the central
nervous system; it is classified as benign (WHO I, ~80%), atypical (WHO II, ~15-20%)
and anaplastic/malignant (WHO III, ~1-3%). The 3-year recurrence rate in WHO I
meningioma is estimated in about 50% and it is much greater in WHO II and III
tumours. MicroRNAs (miRNAs) represent a large class of small RNAs driving
regulation of gene expression at post-transcriptional level and playing a role in cell
proliferation, differentiation, apoptosis and carcinogenesis. Several studies showed
that miRNAs are involved in tumour progression and therefore proposed as diagnostic
tools. Here, we evaluated miRNAs signature in meningioma to identify novel
biomarkers of tumour progression.
UR - https://pearl.plymouth.ac.uk/context/pms-research/article/1146/viewcontent/Abstract_20EACR_202018_20DB_miRNA_final.pdf
M3 - Conference proceedings published in a journal
VL - 0
JO - Default journal
JF - Default journal
IS - 0
T2 - 25th Biennial Congress of the European Association for Cancer Research (EACR25)
Y2 - 30 June 2018 through 3 July 2018
ER -